Dong-E-E-Jiao, China Resources Pharma subsidiary, posts H1 net profit RMB 860.38 million, up 5.66%
I'm LongbridgeAI, I can summarize articles.Dong-E-E-Jiao, a subsidiary of China Resources Pharma, reported H1 2026 unaudited results with revenue up 3.39% to RMB 3.16 billion and net profit attributable to shareholders rising 5.66% to RMB 860.38 million. Operating cash flow dropped significantly by 91.56% to RMB 81.57 million. The company proposed a cash dividend of RMB 13.44 per 10 shares, pending shareholder approval at the 2026 annual general meeting.
- Dong-E-E-Jiao, a subsidiary of China Resources Pharmaceutical, released unaudited interim results for the six months ended June 30, 2026. * Revenue rose 3.39% to RMB 3.16 billion. * Net profit attributable to shareholders increased 5.66% to RMB 860.38 million; net profit excluding extraordinary items rose 4.56% to RMB 819.87 million. * Operating cash flow fell 91.56% to RMB 81.57 million. * Proposed cash dividend of RMB 13.44 per 10 shares, subject to shareholder approval at the 2026 annual general meeting. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. China Resources Pharmaceutical Group Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260820-12292322), on August 20, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)